Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

Transitioning pulmonary arterial hypertension patients from bosentan to macitentan: efficacy and safety data

Mario Santos, Fabienne Gonçalves, Luísa Carvalho, Abílio Reis
European Respiratory Journal 2017 50: PA3536; DOI: 10.1183/1393003.congress-2017.PA3536
Mario Santos
1Pulmonary Vascular Disease Unit, Hospital Santo António, Centro Hospitalar do Porto, Porto, Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fabienne Gonçalves
1Pulmonary Vascular Disease Unit, Hospital Santo António, Centro Hospitalar do Porto, Porto, Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Luísa Carvalho
1Pulmonary Vascular Disease Unit, Hospital Santo António, Centro Hospitalar do Porto, Porto, Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Abílio Reis
1Pulmonary Vascular Disease Unit, Hospital Santo António, Centro Hospitalar do Porto, Porto, Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

Introduction: In addition to several pharmacodynamics advantages over bosentan, macitentan has once-a-day profile, less liver toxicity and drug interactions, and outcome data showing improved mortality and morbidity in pulmonary arterial hypertension (PAH) patients. We aimed to examine the effect of switching bosentan to macitentan on clinical status of PAH patients.

Methods and Results: We conducted a retrospective observational study in a cohort of 32 patients with PAH that transitioned from bosentan to macitentan between 1st January 2015 to 31st December 2016. We compared clinical data at baseline (before starting macitentan) and 6-12 months after (mean time interval of 7±2 months). Mean exposure time for bosentan was 5±2 years. Studied patients had a mean age of 46±17 years and 60% were female. 14 congenital heart disease-associated, 10 idiopathic/heritable, 1 connective-disease associated and 7 chronic thromboembolic disease (CTEPH). No differences were found in NYHA functional class (2.1±0.7 vs 2.1±0.6; p=0.99), 6-minute walking distance (440±121 vs 442±116 m; p=0.68), and proBNP (314 [102-731] vs 386 [124-795] ng/mL; p=0.87) between observations. No differences were observed between group 1 PAH and CTEPH patients. Liver function tests were stable (AST: 21±14 vs 20±17 UI/L, p=0.84; ALT: 21±9 vs 22±10 UI/L, p=0.64). We observed a mean drop of hemoglobin of 0.5±1.4 g/dL in 9 (28%) patients with a >1g/dL decrease (follow-up mean Hb of 15.5±4.0 g/dL).

Conclusions: The switch from bosentan to macitentan was well tolerated and safe. Hemoglobin plasma levels should be monitored as a subset of patients might show a hemoglobin decrease.

  • Copyright ©the authors 2017
Previous
Back to top
Vol 50 Issue suppl 61 Table of Contents
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Transitioning pulmonary arterial hypertension patients from bosentan to macitentan: efficacy and safety data
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Transitioning pulmonary arterial hypertension patients from bosentan to macitentan: efficacy and safety data
Mario Santos, Fabienne Gonçalves, Luísa Carvalho, Abílio Reis
European Respiratory Journal Sep 2017, 50 (suppl 61) PA3536; DOI: 10.1183/1393003.congress-2017.PA3536

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Transitioning pulmonary arterial hypertension patients from bosentan to macitentan: efficacy and safety data
Mario Santos, Fabienne Gonçalves, Luísa Carvalho, Abílio Reis
European Respiratory Journal Sep 2017, 50 (suppl 61) PA3536; DOI: 10.1183/1393003.congress-2017.PA3536
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo

Jump To

  • Article
  • Info & Metrics
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Safety of riociguat for the treatment of pulmonary hypertension: Data from the EXPERT registry
  • Clinical phenotypes and outcomes of pulmonary hypertension due to left heart disease: role of the pre-capillary component
  • Effect of long-term oxygen therapy on exercise capacity and quality of life in exercise-desaturating patients with pulmonary arterial or chronic thromboembolic pulmonary hypertension: a randomized-sham-controlled cross-over trial
Show more Pulmonary Circulation and Pulmonary Vascular Disease

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society